Nanotechnology applications for the therapy of liver fibrosis

Abstract

Chronic liver diseases represent a major global health problem both for their high prevalence worldwide and, in the more advanced stages, for the limited available curative treatment options. In fact, when lesions of different etiologies chronically affect the liver, triggering the fibrogenesis mechanisms, damage has already occurred and the progression of fibrosis will have a major clinical impact entailing severe complications, expensive treatments and death in end-stage liver disease. Despite significant advances in the understanding of the mechanisms of liver fibrinogenesis, the drugs used in liver fibrosis treatment still have a limited therapeutic effect. Many drugs showing potent antifibrotic activities in vitro often exhibit only minor effects in vivo because insufficient concentrations accumulate around the target cell and adverse effects result as other non-target cells are affected. Hepatic stellate cells play a critical role in liver fibrogenesis , thus they are the target cells of antifibrotic therapy. The application of nanoparticles has emerged as a rapidly evolving area for the safe delivery of various therapeutic agents (including drugs and nucleic acid) in the treatment of various pathologies, including liver disease. In this review, we give an overview of the various nanotechnology approaches used in the treatment of liver fibrosis.

Keywords: Liver fibrosis, Nanotechnology, Nanoparticles, Hepatic stellate cells, Antifibrotic drugs, Cirrhosis

Core tip: New drugs or new drug delivery strategies to cure liver fibrosis are needed to find effective therapeutic options for this pathologic condition. Therapies based on nanotechnologies have emerged as an innovative and promising alternative to conventional therapies. This work aims to review the most recent literature about the use of nanotechnology approaches to reduce liver fibrosis.